Immunoglobulin A IgA Vasculitis Global Market Report 2025

The immunoglobulin A (IgA) vasculitis market size has grown strongly in recent years. It will grow from $1.53 billion in 2024 to $1.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to increasing awareness of IgA vasculitis, a rising incidence of autoimmune diseases, greater use of immunosuppressive therapies, increased research funding for rare diseases, and growing adoption of targeted treatment options.

The immunoglobulin A (IgA) vasculitis market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to the increasing use of advanced biomarkers, rising incidence of comorbid conditions, a growing number of clinical trials, heightened interest in biologic therapies, and expanding demand for minimally invasive treatment options. Major trends include the integration of precision medicine, innovations in immunosuppressive therapies, development of disease-modifying treatments, advancements in biomarkers for early diagnosis, and the incorporation of artificial intelligence in treatment planning.

The rising incidence of autoimmune diseases is expected to drive the growth of the immunoglobulin A (IgA) vasculitis market. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own healthy cells, tissues, or organs instead of defending against infections. The increasing prevalence of these disorders is largely attributed to greater exposure to environmental pollutants, which can disrupt immune regulation and trigger abnormal immune responses. IgA vasculitis plays a role in autoimmune diseases by causing inflammation in small blood vessels, providing insights that may aid in understanding and treating various autoimmune conditions. For example, in November 2024, data from Versorgungsatlas.de, a Germany-based organization, reported that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease, corresponding to a raw prevalence rate of 8.61%. Therefore, this rising incidence is propelling the growth of the IgA vasculitis market.

The rising focus on targeted therapies is expected to drive the growth of the immunoglobulin A (IgA) vasculitis market. Targeted therapies are treatments designed to specifically inhibit molecular abnormalities involved in diseases, thereby improving treatment precision and minimizing damage to healthy cells. This growing emphasis on targeted therapies is largely fueled by advancements in precision medicine, which tailors treatments based on an individual’s genetic profile for greater effectiveness. In IgA vasculitis, targeted therapies focus on specific immune pathways, reducing systemic side effects, lowering inflammation, and preventing organ damage - ultimately enhancing patient outcomes and quality of life. For example, in December 2024, the American Society of Gene and Cell Therapy (ASGCT) reported that the FDA approved six gene therapy products in 2023, up from five approvals in 2022, reflecting increased innovation in targeted treatments. Therefore, this rising focus on targeted therapies is propelling the immunoglobulin A vasculitis market forward.

Leading companies in the immunoglobulin A (IgA) vasculitis market are concentrating on creating innovative treatments, including targeted biologics and immunomodulators, aimed at lowering inflammation and preventing kidney-related complications. These advanced therapies work by modulating specific immune pathways to decrease inflammation and protect against immune-driven damage in IgA vasculitis. For example, in April 2025, Novartis AG, a pharmaceutical firm based in Switzerland, obtained approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan) to treat primary immunoglobulin A nephropathy (IgAN). Vanrafia is a selective endothelin A receptor antagonist taken orally once daily, intended to reduce proteinuria in adults with primary IgAN who face a high risk of rapid disease progression. It can be added to current supportive care plans without requiring a risk evaluation and mitigation strategy (REMS).

Major players in the immunoglobulin A (IgA) vasculitis market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Indraprastha Medical Corporation Limited, Intas Pharmaceuticals Ltd, Mayo Clinic, Biogen Inc., Chugai Pharmaceutical Co. Ltd., The Cleveland Clinic Foundation, Zydus Lifesciences Limited, CSL Behring, Artemis Medicare Services Limited, Biocad Biotechnology Company, Biotest AG, Kauvery Hospitals Private Limited, Sheikh Shakhbout Medical City, and Reliance Life Sciences Pvt. Ltd.

North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in immunoglobulin A (IgA) vasculitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the immunoglobulin A (IgA) vasculitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Immunoglobulin A (IgA) vasculitis is an autoimmune disorder marked by inflammation of small blood vessels caused by deposits of IgA antibodies. It primarily affects the skin, joints, kidneys, and gastrointestinal tract, manifesting as purplish rashes, abdominal pain, and joint inflammation.

The main treatment approaches for IgA vasculitis include medications, plasma exchange, supportive care, and immunosuppressive therapy. Medications are mainly aimed at reducing inflammation and managing symptoms such as joint pain, skin rash, and kidney issues resulting from immune reactions triggered by IgA deposits. Diagnosis typically involves blood tests, urinalysis, imaging, and tissue biopsy. Treatments are administered via oral, injectable, or intravenous routes and are provided in hospitals, specialty clinics, and homecare settings.

The immunoglobulin A (IgA) vasculitis market research report is one of a series of new reports that provides immunoglobulin A (IgA) vasculitis market statistics, including the immunoglobulin A (IgA) vasculitis industry's global market size, regional shares, competitors with the immunoglobulin A (IgA) vasculitis market share, detailed immunoglobulin A (IgA) vasculitis market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulin A (IgA) vasculitis market. This immunoglobulin A (IgA) vasculitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunoglobulin A (IgA) vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, renal function monitoring, patient management programs, and clinical research and trials for novel therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The immunoglobulin A (IgA) vasculitis market also includes sales of corticosteroids, pain relievers, diagnostic kits, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.